Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Congenital dysfibrinogenemia

J Martinez1

  • 1Cardeza Foundation for Hematologic Research, Philadelphia, PA 19107-5099, USA.

Current Opinion in Hematology
|September 1, 1997
PubMed
Summary
This summary is machine-generated.

Dysfibrinogenemias are fibrinogen abnormalities with structural defects affecting fibrin formation. These defects, often in fibrinopeptides or polymerization regions, can lead to bleeding or clotting disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bileduct calculi in high-risk patients.

Lancet (London, England)·1996
Same author

Hemorrhagic proctosigmoiditis and Blastocystis hominis infection.

Annals of internal medicine·1996
Same author

Influence of calcium on arachidonic acid mobilization by murine resident peritoneal macrophages.

Archives of biochemistry and biophysics·1995
Same author

Characterization of latex and chestnut antigens by immunoblotting.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·1995
Same author

Predicting survival after coronary revascularization for ischemic cardiomyopathy.

The Annals of thoracic surgery·1995
Same author

Conformationally readdressed CCK-B/delta-opioid peptide ligands.

Biopolymers·1995
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Fibrinogen abnormalities encompass congenital and acquired conditions, including quantitative and qualitative alterations.
  • Qualitative alterations, termed dysfibrinogenemias, result from structural defects impacting fibrinogen to fibrin conversion.
  • Over 300 abnormal fibrinogens and 83 structural defects have been identified, offering insights into fibrinogen's role.

Purpose of the Study:

  • To review the classification and molecular basis of fibrinogen abnormalities, particularly dysfibrinogenemias.
  • To elucidate the clinical manifestations and underlying mechanisms of structural fibrinogen defects.
  • To highlight the contribution of studying abnormal fibrinogens to understanding fibrin formation and dissolution.

Main Methods:

Related Experiment Videos

  • Literature review of reported abnormal fibrinogens and identified structural defects.
  • Analysis of defect locations, focusing on fibrinopeptide cleavage sites and gamma-chain polymerization regions.
  • Correlation of structural abnormalities with clinical outcomes (hemorrhage, thrombosis) and fibrinolysis defects.

Main Results:

  • Dysfibrinogenemias are characterized by structural defects, primarily affecting fibrinopeptide cleavage sites (most common) and gamma-chain polymerization regions.
  • Approximately 50% of identified fibrinogen mutants are clinically silent.
  • Hemorrhage and thrombosis occur with nearly equal frequency in symptomatic cases, with some defects impairing fibrinolysis and promoting thrombosis.

Conclusions:

  • Structural defects in fibrinogen significantly alter its conversion to fibrin and can lead to bleeding or thrombotic events.
  • Specific mutations impact fibrin structure and function, influencing fibrinolysis and potentially causing recurrent thrombosis.
  • The study of dysfibrinogenemias enhances our understanding of fibrinogen structure, function, and its role in hemostasis and thrombosis.